News | April 26, 2024
Laurus Labs posts Q4 FY24 consolidated PAT at Rs. 75.61 Cr
Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024
Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024
Sales reflect continued strong growth in oncology and vaccines
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
Open a printable version of this pageEmail the URL of this page to a friend
Tacrolimus is an immunosuppressant used in the treatment of organ transplant patients
Subscribe To Our Newsletter & Stay Updated
